US-based pharmaceutical company Merck continues to lead the pack, with a dozen digital health deals in the past two years alone.
The digital health sector is on track to raise a record amount in disclosed equity funding this year, with nearly $6B already invested in digital health startups in 2017. And big pharma is taking notice, with companies such as Roche, Amgen, Sanofi, and GlaxoSmithKline recently ramping up their investment into the digital health sector.
We used CB Insights data to create a timeline of digital health investment and acquisition activity by the top 10 pharmaceutical corporates and their associated venture arms. To put this list of corporates together, we looked at the top pharma companies by market cap and spotlighted which were most active in private markets.
We define digital health as companies in the healthcare space that use software as a central piece of the company’s product offering, including but not limited to mobile health, telemedicine, genomics, and electronic medical records. Products like pharmaceuticals, mechanical devices, and hospital systems are excluded from our analysis.
Top pharmaceutical corporates and associated investment arms:
- Johnson & Johnson, Johnson & Johnson Innovation
- Roche, Roche Venture Fund
- Novartis, Novartis Venture Funds
- Pfizer, Pfizer Venture Investments
- Merck, Merck Capital Ventures, Global Health Innovation Fund
- Amgen, Amgen Ventures
- Sanofi, Sanofi-Genzyme Ventures
- Novo Nordisk, Novo Ventures
- GlaxoSmithKline, SR One
Click to enlarge. Orange lines indicate acquisitions. Gray lines indicate equity investments.
Want the full expert post? Become a CB Insights customer.
If you’re already a customer, log in here.